Citi downgrades Progenics Pharmaceuticals Inc (Nasdaq: PGNX) from Hold to Sell. Price target dropped from $19 to $5.

This article: 166 words
-->

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE